Illumina Offered the Counter Bid for Complete Genomics

November 19, 2012

November 18, 2012 | As suspected by many, Illumina says it was the second bidder for Complete Genomics. Complete rejected Illumina's offer--a 5% premium over the BGI offer--because the deal would have likely been stalled by antitrust regulators. Illumina says the offer was in cash. Bloomberg